argenx (ARGX)

• Market cap: $38.3B
• 1 day: -2.92%
• 5 days: -2.75%
• 1 month: 0.34%
• 3 months: 17.78%
• 6 months: 38.22%
• Year to date: 3.28%
• 1 year: 71.98%
• 5 years: 314.87%
• 10 years: 2,684.87%

About: Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

Employees: 1,148

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

69% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 32

25% more capital invested

Capital invested by funds: $15.1B [Q2] → $19B (+$3.84B) [Q3]

16% more repeat investments, than reductions

Existing positions increased: 133 | Existing positions reduced: 115

6% more funds holding

Funds holding: 331 [Q2] → 350 (+19) [Q3]

6% more call options, than puts

Call options by funds: $292M | Put options by funds: $275M

0% more funds holding in top 10

Funds holding in top 10: 20 [Q2] → 20 (+0) [Q3]

0.66% less ownership

Funds ownership: 59.27% [Q2] → 58.61% (-0.66%) [Q3]

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $650 1% upside
• Avg. target: $695 8% upside
• High target: $725 13% upside

12 analyst ratings

• positive: 11 92%
• neutral: 1 8%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 33% 1-year accuracy 56 / 172 met price target	12% upside $717	Buy Reiterated	14 Jan 2025
Truist Securities Joon Lee 49% 1-year accuracy 20 / 41 met price target	9% upside $700	Buy Reiterated	14 Jan 2025
JMP Securities Jason Butler 31% 1-year accuracy 13 / 42 met price target	9% upside $696	Market Outperform Maintained	14 Jan 2025
Piper Sandler Allison Bratzel 80% 1-year accuracy 8 / 10 met price target	13% upside $725	Overweight Maintained	7 Jan 2025
Wells Fargo Derek Archila 44% 1-year accuracy 16 / 36 met price target	13% upside $723	Overweight Maintained	19 Dec 2024